Amarin Corp Plc (AMRN)

[Biobillionair]

Reason for second Nevada suit:

On information and belief, and as stated in a letter dated June 1, 2020 sent by
Defendants to Amarin (the “June Notice Letter”), Defendants prepared and filed patent
certifications with the FDA in support of amended ANDA No. 209457 with the intention of
seeking to market a generic version of the 0.5 gram strength of Amarin’s VASCEPA® product
(“generic VASCEPA® 0.5 g product”), including within this judicial district. Amarin received
the June Notice Letter on June 2, 2020.

BB